The global hydrogel-based drug delivery system market size is anticipated to reach USD 11.77 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.7% from 2024 to 2030. Hydrogels help in achieving spatial and temporal control over the release of the incorporated drug. Therefore, the surging demand for controlled releases drug delivery system across many therapeutic areas is a key factor expected to contribute to market growth during the forecast period.
Hydrogel-based drug delivery systems deliver the therapeutic drug directly at the target site and in a sustained manner. This can leverage beneficial outcomes such as improved efficacy, reduced side effects, and decreased dosage for patients and formulators. Hydrogel-based drug delivery systems are appealing and have been used in many branches of medicine such as oncology, pain management, immunology, cardiology, and wound management.
The unique physical properties of hydrogel attract their interest in use for drug delivery applications. The porosity and drug loading capacity of hydrogels can be adjusted by modifying the density of cross-linking. This helps them to protect liable large drug molecules from degradation increasing the half-life. Many research studies have been carried out to examining the delivery of insulin orally using hydrogel systems. As patient compliance issues are frequently reported with injectable insulins such innovation is expected to be a disruptive technology in the diabetes care market.
There are numerous clinical studies underway specific to hydrogel-based drug delivery systems and various hydrogel technologies have already received regulatory approval for biomedical application. However, the technological challenges including the absence of defined regulatory guidelines, chemistry, complex manufacturing and control paraments, and practical adaptability are major roadblocks in the successful implementation in drug delivery use. For instance, the fabrication of hydrogel is complex and varies significantly depending upon the hydrogel systems.
Request a free sample copy or view report summary: Hydrogel-based Drug Delivery System Market Report
Based on polymer origin, the synthetic segment held the largest proportion of market share in 2023
The hybrid segment is expected to witness the fastest growth rate over the forecast period owing to the development of stimuli-responsive hydrogel technology
The synthetic segment is anticipated to grow fast over the forecast period compared to natural hydrogels due to their high drug loading capacity and improved mechanical strength
Based on delivery route, the ocular segment accounted for the largest revenue share in 2023
The subcutaneous segment is expected to grow at a healthy rate over the forecast period owing to the increasing number of clinical and pre-clinical studies carried out
North America holds the largest revenue share in this market due to the presence of key companies in the region doing R&D on specific hydrogel-based drug delivery systems
In Asia Pacific, the market is expected to grow at the fastest rate over the forecast period due to large patient base, improving healthcare infrastructure, and surging demand for modern therapies
Grand View Research has segmented the global hydrogel-based drug delivery system market report based on polymer origin, delivery route, and region:
Hydrogel-based Drug Delivery System Polymer Origin Outlook (Revenue, USD Million, 2018 - 2030)
Natural
Synthetic
Hybrid
Hydrogel-based Drug Delivery System Delivery Route Outlook (Revenue, USD Million, 2018 - 2030)
Subcutaneous
Ocular
Oral Cavity
Topical
Other
Hydrogel-based Drug Delivery System Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Asia Pacific
China
Japan
India
Thailand
South Korea
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Hydrogel-based Drug Delivery System Market
GALDERMA
Blairex Laboratories, Inc
Johnson & Johnson
Bausch + Lomb.
Medtronic
Ocular Therapeutix, Inc.
Ferring B.V.
Endo, Inc.
Tolmar Inc
"The quality of research they have done for us has been excellent..."